Blue Calypso to Conduct Q4/FYE 2015 Financial Results Conference Call
Mar 17, 2016 11:00 am UTC| Business
DALLAS, March 17, 2016 -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for manufacturers and brick-and-mortar retailers, is scheduled to host a...
Voyager Therapeutics Provides Fourth Quarter and Full Year 2015 Investor Update
Mar 17, 2016 11:00 am UTC| Business
Top-line Clinical Proof-of-Concept Data for VY-AADC01 for Advanced Parkinson’s Disease On Track for Release in the Fourth Quarter of 2016 Strong Cash Position Projected to Support Operations into 2019 CAMBRIDGE, Mass.,...
Admera Health Launches Molecular Test for Inherited Early Atherosclerosis Diagnosis and Risk
Mar 17, 2016 11:00 am UTC| Business
SOUTH PLAINFIELD, N.J., March 17, 2016 -- Admera Health (www.admerahealth.com), a commercial stage New Jersey based Precision Medicine and Digital Health company announced today the launch of AtheroGxOne™ following its...
Biota Pharmaceuticals Announces Sale of Antibiotic Assets to Spero Therapeutics
Mar 17, 2016 10:30 am UTC| Business
ATLANTA, March 17, 2016 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that it has completed the sale of assets related to its broad spectrum antibiotic program to a newly formed subsidiary of Spero...
Mar 17, 2016 10:18 am UTC| Business
Deerfield Beach, FL, March 17, 2016 -- Zion Research has released a new report titled “Car Rental (Luxury Cars, Executive Cars, Economy Cars, SUV Cars, and MUV Cars) Market for Local Usage, Airport Transport,...
Affimed to Present Data on NK- and T-Cell Engagers at the AACR Annual Meeting 2016
Mar 17, 2016 10:00 am UTC| Business
--AFM13/anti-PD-1 combination induces cross-talk between innate and adaptive immunity-- --TandAbs targeting EGFRvIII and EGFRwt are highly potent drug candidates to treat EGFR-related cancers-- HEIDELBERG, Germany,...
Mar 17, 2016 10:00 am UTC| Business
NEW YORK and MELBOURNE, Australia, March 17, 2016 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Company has exclusively licensedpatented technology developed at Harvard Medical School which can...